logo
Share SHARE
FONT-SIZE Plus   Neg

Interesting Stocks To Watch - Nov. 8: FLDM, IDSY, QCOM, EAC, GCA, CTL, NCIT...

What makes these stocks interesting?

Fluidigm Corp. (FLDM) Issues FY12 Guidance

- Now expects FY12 product revenue to grow 24% - 26% over prior year's product revenue of $40.6 mln.

- Projects FY12 grant revenue is expected to be about $0.6 mln.

***

I.D. Systems Inc. (IDSY) Swings To Profit In Q3

- Q3 net income was $2.2 mln or $0.18/Shr versus loss $214K or $0.02 last year.

- Q3 non-GAAP net income was $3.0 mln or $0.25/Shr versus $665K or $0.06 last year. Consensus - $0.27/Shr.

- Q3 revenue rose 37% to $15.5 mln from $11.3 mln a year ago. Consensus - $17.26 mln.

***

Qualcomm Inc. (QCOM) Q4 Profit Rises; Issues Q1, FY13 Outlook

- Projects Q1 GAAP EPS in the range of $0.90 - $0.98.

- Expects Q1 non-GAAP EPS in the range of $1.08 - $1.16. Consensus - $1.00/Shr.

- Sees Q1 revenues between $5.6 bln and $6.1 bln. Consensus - $5.29 bln.

- Expects FY13 GAAP EPS in the range of $3.40 - $3.60

- Expects FY13 non-GAAP EPS in the range of $4.12 - $4.32. Consensus - $4.13/Shr.

- Projects FY13 revenues in the range of $23.0 bln - $24.0 bln. Consensus - $21.69 bln.

***

Erickson Air-Crane Inc. (EAC) Lifts FY12 Guidance

- Raises FY12 pro forma EPS target to $1.34 - $1.55 from prior outlook of $0.76 - $0.86. Consensus - $1.10/Shr.

- Lifts FY12 GAAP EPS estimate to a range of $1.86 - $2.15 from prior forecast range of $1.05 - $1.20.

- Now sees FY12 revenues to range between $177.0 mln and $181.0 mln, up from prior view of $159.0 mln - $165.0 mln. Consensus - $162.76 mln.

***

Global Cash Access Holdings Inc. (GCA) Raises FY12 Outlook

- Lifts FY12 cash EPS target to $0.81 - $0.84 from prior estimate of $0.76 - $0.82. Consensus - $0.79/Shr.

***

CenturyLink Inc. (CTL) Q3 Profit Rises; Lifts FY12 Adj. EPS View

- Projects Q4 adj. EPS to range between $0.64 and $0.69. Consensus - $0.62/Shr.

- Expects Q4 opt. Revenue in the range of $4.56 bln - $4.61 bln. Consensus - $4.58 bln.

- Lifts FY12 adj. EPS target to $2.64 - $2.69 from prior view of $2.45 - $2.55. Consensus - $2.53/Shr.

- Now sees FY12 opt. revenue in the range of $18.35 bln - $18.4 bln versus prior estimate of $18.3 bln - $18.4 bln. Consensus - $18.37 bln.

***

NCI Inc. (NCIT) Sees Q4, FY12 Results Above Consensus

- Projects Q4 adj. EPS in the range of $0.10 - $0.12. Consensus - $0.06/Shr.

- Expects Q4 revenue in the range of $85 mln - $91 mln. Consensus - $83.71 mln.

- Expects FY12 adj. EPS to range between $0.46 and $0.48. Consensus - $0.36/Shr.

- Projects FY12 revenue in the range of $364 mln - $370 mln. Consensus - $359.99 mln.

***

Sapient Corp. (SAPE) Q3 Profit Rises

- Q3 net income was $21.5 mln or $0.15/Shr versus $19.8 mln or $0.14/Shr last year.

- Q3 adj. net income was $28.0 mln or $0.20/Shr versus $25.7 mln or $0.18/Shr last year. Consensus - $0.13/Shr.

- Q3 service revenues grew to $288.5 mln from $262.7 mln last year. Consensus - $281.34 mln.

- Prior to the impact of Hurricane Sandy, the company was expecting Q4 service revenues of $289 mln - $294 mln. The company said it is still assessing the impact, and estimates Q4 revenues to be $1 mln - $2 mln less. Consensus - $281.34 mln.

***

Tower Group Inc. (TWGP) Turns To Profit In Q3; Sees FY13 opt. EPS Above Consensus

- Projects FY13 operating EPS in the range of $2.85 - $3.05. Consensus - $0.65/Shr.

***

POZEN Achieves Primary Endpoint In Two Late-Stage Studies

Pharmaceutical company POZEN Inc. (POZN) said patients on its experimental drug PA32540 experienced fewer Gastric Ulcers, while maintaining cardiovascular benefits compared to those on Aspirin alone. The company derived the data from two pivotal Phase 3 trials.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
RELATED NEWS
Trade GCA now with 
Follow RTT